Mithra Pharmaceuticals S.A. Stock

Equities

MITRA

BE0974283153

Pharmaceuticals

Market Closed - Euronext Bruxelles 11:35:26 2024-04-26 am EDT 5-day change 1st Jan Change
0.216 EUR -1.82% Intraday chart for Mithra Pharmaceuticals S.A. -.--% -82.78%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2023 40.16M 43.64M Sales 2024 * 43.9M 47.71M Capitalization 14.93M 16.22M
Net income 2023 -174M -189M Net income 2024 * -55M -59.77M EV / Sales 2023 9.88 x
Net Debt 2023 310M 337M Net cash position 2024 * - 0 EV / Sales 2024 * 0.34 x
P/E ratio 2023 *
-0.16 x
P/E ratio 2024 *
-
Employees 270
Yield 2023 *
-
Yield 2024 *
-
Free-Float 81.67%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.82%
1 month-2.04%
3 months-63.58%
6 months-82.58%
Current year-82.78%
More quotes
1 week
0.22
Extreme 0.2155
0.22
1 month
0.22
Extreme 0.2155
0.23
Current year
0.20
Extreme 0.201
1.36
1 year
0.20
Extreme 0.201
3.87
3 years
0.20
Extreme 0.201
25.05
5 years
0.20
Extreme 0.201
32.96
10 years
0.20
Extreme 0.201
39.35
More quotes
Managers TitleAgeSince
Chief Executive Officer - 17-02-22
Chief Tech/Sci/R&D Officer - 21-04-30
Chief Tech/Sci/R&D Officer 63 19-03-31
Members of the board TitleAgeSince
Director/Board Member 53 23-05-28
Chairman 65 23-05-28
Director/Board Member 51 21-05-19
More insiders
Date Price Change Volume
24-05-17 0.216 -.--% 0
24-05-16 0.216 -.--% 0
24-05-15 0.216 -.--% 0
24-05-14 0.216 -.--% 0
24-05-13 0.216 -.--% 0

Real-time Euronext Bruxelles, April 26, 2024 at 11:35 am EDT

More quotes
Mithra Pharmaceuticals S.A. is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra Pharmaceuticals S.A. explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle®, the Company is now focusing on its second product Donesta®, the next-generation hormone therapy. Mithra Pharmaceuticals S.A. also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
0.216 EUR
Average target price
0.1 EUR
Spread / Average Target
-53.70%
Consensus

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW